{"id":9778,"date":"2025-10-13T06:34:33","date_gmt":"2025-10-13T11:34:33","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9778"},"modified":"2025-10-13T07:34:38","modified_gmt":"2025-10-13T12:34:38","slug":"nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","title":{"rendered":"Nanoscope Therapeutics anuncia varias presentaciones en la reuni\u00f3n anual de la Academia Estadounidense de Oftalmolog\u00eda de 2025."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a013 de octubre de 2025<\/span>\u00a0 \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy m\u00faltiples presentaciones en el\u00a0Academia Americana de Oftalmolog\u00eda<\/i>\u00a0Reuni\u00f3n Anual de la AAO 2025<\/a>, que se celebrar\u00e1 del 18 al 20 de octubre de 2025 en Orlando, Florida, as\u00ed como en\u00a0Eyecelerator@AAO 2025<\/a><\/i>,<\/i>\u00a0El 16 de octubre de 2025, tambi\u00e9n en Orlando.<\/p>

Nanoscope presentar\u00e1 su plataforma patentada Multi-Characteristic Opsin (MCO), dise\u00f1ada para restaurar la visi\u00f3n en pacientes con p\u00e9rdida grave de visi\u00f3n debido a la retinosis pigmentaria (RP) y la enfermedad de Stargardt (SD), dos afecciones debilitantes para las que actualmente no existen tratamientos aprobados.<\/p>

Detalles de la presentaci\u00f3n:<\/p>

T\u00edtulo:<\/b>\u00a0\u201cPresentaci\u00f3n de la empresa Nanoscope Therapeutics\u201d (Eyecelerator @AAO 2025)
<\/i>Sesi\u00f3n:\u00a0<\/b>Posterior\/Retiniana
<\/i>Fecha \/ Hora:<\/b>\u00a0Jueves, 16 de octubre de 2025 | 13:40-13:45 (hora del este de EE. UU.)
Ubicaci\u00f3n:<\/b>\u00a0W230
Presentador:\u00a0<\/b>Samuel Barone, MD, Director M\u00e9dico de Nanoscope Therapeutics<\/a><\/p>

T\u00edtulo:<\/b>\u00a0\u201cDatos del estudio REMAIN de 152 semanas, procedentes del an\u00e1lisis ampliado del estudio MCO-010 RESTORE sobre terapia optogen\u00e9tica para la retinosis pigmentaria\u201d
<\/i>Sesi\u00f3n:<\/b>\u00a0Secci\u00f3n XI: \u00daltimas noticias, Parte II
Fecha \/ Hora:<\/b>\u00a0S\u00e1bado, 18 de octubre de 2025 | 8:11-8:18 a. m. EDT
Ubicaci\u00f3n:<\/b>\u00a0W415 Valencia
Presentador:<\/b>\u00a0Allen C. Ho, MD, FACS, FASRS, Cirujano Adjunto y Director de Investigaci\u00f3n de Retina, Wills Eye Hospital; Asesor M\u00e9dico Jefe, Nanoscope Therapeutics<\/a>.<\/p>

T\u00edtulo:<\/b>\u00a0\u201cMejora visual en m\u00faltiples evaluaciones con la terapia optogen\u00e9tica MCO-010 para la enfermedad de Stargardt\u201d
<\/i>Sesi\u00f3n:<\/b>\u00a0Mesa redonda sobre p\u00f3steres: Retina, v\u00edtreo
Fecha \/ Hora:<\/b>\u00a0S\u00e1bado, 18 de octubre de 2025 | 13:45-14:15 (hora del este de EE. UU.)
Ubicaci\u00f3n:\u00a0<\/b>Sala WB4, Estaci\u00f3n 1
Presentador:<\/b>\u00a0Kenneth C. Fan, MD, Consultores de Retina de Texas<\/a><\/p>

T\u00edtulo:<\/i><\/b>\u00a0\u00a0\u201cTerapia optogen\u00e9tica en adultos con retinosis pigmentaria y enfermedad de Stargardt\u201d
<\/i>Sesi\u00f3n:<\/b>\u00a0Enfoques terap\u00e9uticos para la restauraci\u00f3n de la visi\u00f3n
Fecha \/ Hora:<\/b>\u00a0Lunes, 20 de octubre de 2025 | 8:30-8:45 a. m. EDT
Ubicaci\u00f3n:<\/b>\u00a0W311E
Presentador:\u00a0<\/b>Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico de Nanoscope Therapeutics<\/a>; y\u00a0Stephen Tsang, MD, PhD, Universidad de Columbia, Centro M\u00e9dico Irving<\/a>.<\/p>

\u201cEsperamos compartir y debatir los \u00faltimos datos de MCO-010 en AAO y Eyecelerator 2025\u201d, dijo.\u00a0Sulagna Bhattacharya, directora ejecutiva<\/a>. Estas presentaciones ponen de manifiesto la solidez de nuestra base cl\u00ednica y regulatoria. Con la solicitud de licencia biol\u00f3gica (BLA) para la retinosis pigmentaria (RP) en curso y cinco nuevas designaciones de medicamento hu\u00e9rfano otorgadas por la Agencia Europea de Medicamentos (EMA), estamos impulsando un fuerte impulso global para que MCO-010 llegue a los pacientes afectados por enfermedades retinianas que causan ceguera.\u201c<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a finales de 2025. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Oct. 13, 2025\u00a0 \u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced multiple presentations at the\u00a0American Academy of Ophthalmology\u00a0(AAO) 2025 Annual Meeting, to be held October 18-20, 2025 in Orlando, FL, as well as at\u00a0Eyecelerator@AAO 2025,\u00a0on […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T11:34:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T12:34:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting\",\"datePublished\":\"2025-10-13T11:34:33+00:00\",\"dateModified\":\"2025-10-13T12:34:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"},\"wordCount\":605,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-10-13T11:34:33+00:00\",\"dateModified\":\"2025-10-13T12:34:38+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia m\u00faltiples presentaciones en la Reuni\u00f3n Anual de la Academia Estadounidense de Oftalmolog\u00eda de 2025 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-10-13T11:34:33+00:00","article_modified_time":"2025-10-13T12:34:38+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting","datePublished":"2025-10-13T11:34:33+00:00","dateModified":"2025-10-13T12:34:38+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"},"wordCount":605,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","name":"Nanoscope Therapeutics anuncia m\u00faltiples presentaciones en la Reuni\u00f3n Anual de la Academia Estadounidense de Oftalmolog\u00eda de 2025 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-10-13T11:34:33+00:00","dateModified":"2025-10-13T12:34:38+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9778"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9778\/revisions"}],"predecessor-version":[{"id":9786,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9778\/revisions\/9786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}